Maze Therapeutics Q1 EPS $(1.15) Up From $(13.91) YoY

Maze Therapeutics (NASDAQ: MAZE) reported quarterly losses of $(1.15) per share. This is a 91.73 percent increase over losses of $(13.91) per share from the same period last year.